DIAGNOSTIC AND THERAPEUTIC ROLE OF MESOPOROUS SILICA NANOPARTICLES IN COMBATING CANCER

NUPUR KATARIYA; ARVIND SINGH FARSWAN; NIDHI NAINWAL; GANESH KUMAR

doi:10.22159/ijap.2024v16i5.51647

Authors

NUPUR KATARIYA Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Premnagar, Dehradun-248007, Uttarakhand, India
ARVIND SINGH FARSWAN Himalayan School of Pharmaceutical Sciences, Swami Ram Himalayan University, Jolly Grant, Dehradun-248016, Uttarakhand, India https://orcid.org/0000-0002-7773-8324
NIDHI NAINWAL Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Premnagar, Dehradun-248007, Uttarakhand, India https://orcid.org/0000-0003-0117-1701
GANESH KUMAR Himalayan School of Pharmaceutical Sciences, Swami Ram Himalayan University, Jolly Grant, Dehradun-248016, Uttarakhand, India

DOI:

https://doi.org/10.22159/ijap.2024v16i5.51647

Keywords:

Mesoporous silica nanoparticles, Cancer, Applications, Therapeutics, Diagnostics

Abstract

Cancer is a global health problem of human beings that is growing day by day despite several advancements in the medical field. The main concern of cancer treatment is the timely and proper diagnosis of this disease and the targeting of therapeutic moieties to the cancer site. Nanotechnology has emerged as a boon for the healthcare system in treating various life-threatening diseases. Mesoporous Silica Nanoparticles (MSNs), have drawn interest in the diagnosis and treatment of cancers and various other diseases. MSNs can be easily adjusted to specifically target cancer cells, improve drug targeting and minimize the undesirable effects. In the imaging and diagnosis of cancer, MSNs can be altered with imaging agents or used as contrast agents in imaging techniques like Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). MSNs can be used to deliver different types of therapeutic molecules alone or in combinations to provide a synergistic effect in eradicating cancer. The current review focused on highlighting the role of MSNs in combating cancer. In addition, the biodegradation, clearance and toxicity profile of MSNs is explained to evaluate their suitability for clinical applications.

Downloads

Download data is not yet available.

References

Aghebati Maleki A, Dolati S, Ahmadi M, Baghbanzhadeh A, Asadi M, Fotouhi A. Nanoparticles and cancer therapy: perspectives for application of nanoparticles in the treatment of cancers. J Cell Physiol. 2020;235(3):1962-72. doi: 10.1002/jcp.29126, PMID 31441032.

Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC. Colorectal cancer statistics 2020. CA Cancer J Clin. 2020;70(3):145-64. doi: 10.3322/caac.21601, PMID 32133645.

Kiran AVVVR, Kumari GK, Krishnamurthy PT. Carbon nanotubes in drug delivery: focus on anticancer therapies. J Drug Deliv Sci Technol. 2020;59:101892. doi: 10.1016/j.jddst.2020.101892.

Rastegari E, Hsiao YJ, Lai WY, Lai YH, Yang TC, Chen SJ. An update on mesoporous silica nanoparticle applications in nanomedicine. Pharmaceutics. 2021;13(7)1067. doi: 10.3390/pharmaceutics13071067, PMID 34371758.

Ale Y, Nainwal N. Progress and challenges in the diagnosis and treatment of brain cancer using nanotechnology. Mol Pharm. 2023;20(10):4893-921. doi: 10.1021/acs.molpharmaceut.3c00554, PMID 37647568.

Kankala RK, Liu CG, Yang DY, Wang SB, Chen AZ. Ultrasmall platinum nanoparticles enable deep tumor penetration and synergistic therapeutic abilities through free radical species assisted catalysis to combat cancer multidrug resistance. Chem Eng J. 2020;383:123138. doi: 10.1016/j.cej.2019.123138.

Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy. Int J Mol Sci. 2020;21(9):3233. doi: 10.3390/ijms21093233, PMID 32370233.

He Q, Shi J. MSN anticancer nanomedicines: chemotherapy enhancement overcoming of drug resistance and metastasis inhibition. Adv Mater. 2014;26(3):391-411. doi: 10.1002/ADMA.201303123, PMID 24142549.

Sharifi F, Nazir I, Asim MH, Jahangiri M, Ebrahimnejad P, Matuszczak B. Zeta potential changing self emulsifying drug delivery systems utilizing a novel Janus-headed surfactant: a promising strategy for enhanced mucus permeation. J Mol Liq. 2019;291:111285. doi: 10.1016/j.molliq.2019.111285.

Rahikkala A, Pereira SA, Figueiredo P, Passos ML, Araujo AR, Saraiva ML. Mesoporous silica nanoparticles for targeted and stimuli responsive delivery of chemotherapeutics: a review. Adv Biosys. 2018;2(7):1800020. doi: 10.1002/adbi.201800020.

Shchipunov YA, Burtseva YV, Karpenko TY, Shevchenko NM, Zvyagintseva TN. Highly efficient immobilization of endo-1,3-β-d-glucanases (laminarinases) from marine mollusks in novel hybrid polysaccharide silica nanocomposites with regulated composition. Journal of Molecular Catalysis B: Enzymatic. 2006;40(1-2):16-23. doi: 10.1016/j.molcatb.2006.02.002.

Ghaferi M, Koohi Moftakhari Esfahani M, Raza A, Al Harthi S, Ebrahimi Shahmabadi H, Alavi SE. Mesoporous silica nanoparticles: synthesis methods and their therapeutic use recent advances. J Drug Target. 2021;29(2):131-54. doi: 10.1080/1061186X.2020.1812614, PMID 32815741.

Liu M, Zhao Y, Shi Z, Zink JI, Yu Q. Virus like magnetic mesoporous silica particles as a universal vaccination platform against pathogenic infections. ACS Nano. 2023;17(7):6899-911. doi: 10.1021/acsnano.3c00644, PMID 36961475.

Bharti C, Nagaich U, Pal AK, Gulati N. Mesoporous silica nanoparticles in target drug delivery system: a review. Int J Pharm Investig. 2015;5(3):124-33. doi: 10.4103/2230-973X.160844, PMID 26258053.

Asefa T, Tao Z. Biocompatibility of mesoporous silica nanoparticles. Chem Res Toxicol. 2012;25(11):2265-84. doi: 10.1021/tx300166u, PMID 22823891.

Narayan R, Nayak UY, Raichur AM, Garg S. Mesoporous silica nanoparticles: a comprehensive review on synthesis and recent advances. Pharmaceutics. 2018;10(3):118. doi: 10.3390/pharmaceutics10030118, PMID 30082647.

Liu X, Jiang Y, Cai P, Gao R. Editorial: advanced silica nanomaterials for drug delivery. Front Chem. 2021;9:677647. doi: 10.3389/fchem.2021.677647, PMID 33959591.

Suwalski A, Dabboue H, Delalande A, Bensamoun SF, Canon F, Midoux P. Accelerated achilles tendon healing by PDGF gene delivery with mesoporous silica nanoparticles. Biomaterials. 2010;31(19):5237-45. doi: 10.1016/j.biomaterials.2010.02.077, PMID 20334910.

Lozano D, Trejo CG, Gomez Barrena E, Manzano M, Doadrio JC, Salinas AJ. Osteostatin loaded onto mesoporous ceramics improves the early phase of bone regeneration in a rabbit osteopenia model. Acta Biomater. 2012;8(6):2317-23. doi: 10.1016/j.actbio.2012.03.014, PMID 22414621.

Vallet Regi M. Ordered mesoporous materials in the context of drug delivery systems and bone tissue engineering. Chemistry. 2006;12(23):5934-43. doi: 10.1002/chem.200600226, PMID 16832799.

Sinha P, Rathnam G, SM DK, N JK. Overview on carbondots. Int J Curr Pharm Sci. 2023;15(4):9-14. doi: 10.22159/ijcpr.2023v15i4.3013.

Joshi P, Nainwal N, Morris S, Jakhmola V. A review on recent advances on stimuli based smart nanomaterials for drug delivery and biomedical application. Int J App Pharm. 2023;15(5):48-59. doi: 10.22159/ijap.2023v15i5.48186.

Phalak SD, Bodke V, Yadav R, Pandav S, Ranaware M. A systematic review on nano drug delivery system: solid lipid nanoparticles (sln). Int J Curr Pharm Sci. 2024;16(1):10-20. doi: 10.22159/ijcpr.2024v16i1.4020.

Gu L, Lin J, Wang Q, Meng F, Niu G, Lin H. Mesoporous zinc oxide based drug delivery system offers an antifungal and immunoregulatory strategy for treating keratitis. J Control Release. 2024;368:483-97. doi: 10.1016/j.jconrel.2024.03.006, PMID 38458571.

Su X, Li B, Chen S, Wang X, Song H, Shen B. Pore engineering of micro mesoporous nanomaterials for encapsulation controlled release and variegated applications of essential oils. J Control Release. 2024;367:107-34. doi: 10.1016/j.jconrel.2024.01.005, PMID 38199524.

Article, Gharat S, Ghadge A, Phalak SD, Bodke V, Gavand A, Ganvir D. A review on template synthesis of nanoparticle. Int J Pharm Pharm Sci. 2024;16(5):22-9. doi: 10.22159/ijpps.2024v16i5.50661.

Bhosale RR, Janugade BU, Chavan DD, Thorat VM. Current perspectives on applications of nanoparticles for cancer management. Int J Pharm Pharm Sci. 2023:15(11):1-10. doi: 10.22159/ijpps.2023v15i11.49319.

Janjua TI, Cao Y, Ahmed Cox A, Raza A, Moniruzzaman M, Akhter DT. Efficient delivery of temozolomide using ultrasmall large pore silica nanoparticles for glioblastoma. J Control Release. 2023;357:161-74. doi: 10.1016/j.jconrel.2023.03.040, PMID 36965857.

Vallet Regi M, Colilla M, Izquierdo Barba I, Manzano M. Mesoporous silica nanoparticles for drug delivery: current insights. Molecules. 2017;23(1):47. doi: 10.3390/MOLECULES23010047, PMID 29295564.

Li L, Liu H. Biodegradable inorganic nanoparticles: an opportunity for improved cancer therapy. Nanomedicine (Lond). 2017;12(9):959-61. doi: 10.2217/nnm-2017-0057, PMID 28440705.

Croissant JG, Fatieiev Y, Almalik A, Khashab NM. Mesoporous silica and organosilica nanoparticles: physical chemistry biosafety delivery strategies and biomedical applications. Adv Healthc Mater. 2018;7(4). doi: 10.1002/adhm.201700831, PMID 29193848.

Wu SH, Hung Y, Mou CY. Mesoporous silica nanoparticles as nanocarriers. Chem Commun (Camb). 2011;47(36):9972-85. doi: 10.1039/c1cc11760b, PMID 21716992.

Lu J, Liong M, Li Z, Zink JI, Tamanoi F. Biocompatibility biodistribution and drug delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small. 2010;6(16):1794-805. doi: 10.1002/smll.201000538, PMID 20623530.

Zhao Y, Trewyn BG, Slowing II, Lin VS. Mesoporous silica nanoparticle based double drug delivery system for glucose responsive controlled release of insulin and cyclic AMP. J Am Chem Soc. 2009;131(24):8398-400. doi: 10.1021/ja901831u, PMID 19476380.

Moulari B, Pertuit D, Pellequer Y, Lamprecht A. The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis. Biomaterials. 2008;29(34):4554-60. doi: 10.1016/j.biomaterials.2008.08.009, PMID 18790531.

Padiyar N, Nainwal N, Ale Y, Galwan D. Formulation characterization and stability aspects of mesoporous silica nanoparticles. Int J Drug Deliv Technol. 2024;14(2):1217-24. doi: 10.25258/ijddt.14.2.88.

Blasiak B, Van Veggel FC, Tomanek B. Applications of nanoparticles for MRI cancer diagnosis and therapy. J Nanomater. 2013;2013(1). doi: 10.1155/2013/148578.

Frangioni JV. New technologies for human cancer imaging. J Clin Oncol. 2008;26(24):4012-21. doi: 10.1200/JCO.2007.14.3065, PMID 18711192.

Thakor AS, Gambhir SS. Nanooncology: the future of cancer diagnosis and therapy. CA Cancer J Clin. 2013;63(6):395-418. doi: 10.3322/caac.21199, PMID 24114523.

Rosenholm JM, Sahlgren C, Linden M. Multifunctional mesoporous silica nanoparticles for combined therapeutic diagnostic and targeted action in cancer treatment. Curr Drug Targets. 2011;12(8):1166-86. doi: 10.2174/138945011795906624, PMID 21443474.

Wu X, Wu M, Zhao JX. Recent development of silica nanoparticles as delivery vectors for cancer imaging and therapy. Nanomedicine. 2014;10(2):297-312. doi: 10.1016/j.nano.2013.08.008.

Pericleous P, Gazouli M, Lyberopoulou A, Rizos S, Nikiteas N, Efstathopoulos EP. Detection of colorectal circulating cancer cells with the use of a quantum dot labelled magnetic immunoassay method. Hellenic J Surg. 2013;85(2):127-34. doi: 10.1007/s13126-013-0025-5.

Zheng T, Pierre Pierre N, Yan X, Huo Q, Almodovar AJ, Valerio F. Gold nanoparticle enabled blood test for early stage cancer detection and risk assessment. ACS Appl Mater Interfaces. 2015;7(12):6819-27. doi: 10.1021/acsami.5b00371, PMID 25757512.

Feng Y, Panwar N, Tng DJ, Tjin SC, Wang K, Yong KT. The application of mesoporous silica nanoparticle family in cancer theranostics. Coord Chem Rev. 2016;319:86-109. doi: 10.1016/j.ccr.2016.04.019.

Jasanoff A. MRI contrast agents for functional molecular imaging of brain activity. Curr Opin Neurobiol. 2007;17(5):593-600. doi: 10.1016/j.conb.2007.11.002, PMID 18093824.

Ahveninen J, Lin FH, Kivisaari R, Autti T, Hamalainen M, Stufflebeam S. MRI-constrained spectral imaging of benzodiazepine modulation of spontaneous neuromagnetic activity in human cortex. Neuroimage. 2007;35(2):577-82. doi: 10.1016/j.neuroimage.2006.12.033, PMID 17300962.

Hsiao JK, Tsai CP, Chung TH, Hung Y, Yao M, Liu HM. Mesoporous silica nanoparticles as a delivery system of gadolinium for effective human stem cell tracking. Small. 2008;4(9):1445-52. doi: 10.1002/SMLL.200701316, PMID 18680095.

Kim T, Momin E, Choi J, Yuan K, Zaidi H, Kim J. Mesoporous silica coated hollow manganese oxide nanoparticles as positive T1 contrast agents for labeling and MRI tracking of adipose derived mesenchymal stem cells. J Am Chem Soc. 2011;133(9):2955-61. doi: 10.1021/JA1084095, PMID 21314118.

Cheng B, He H, Huang T, Berr SS, He J, Fan D. Gold nanosphere gated mesoporous silica nanoparticle responsive to near infrared light and redox potential as a theranostic platform for cancer therapy. J Biomed Nanotechnol. 2016;12(3):435-49. doi: 10.1166/JBN.2016.2195, PMID 26949379.

Liu HM, Wu SH, Lu CW, Yao M, Hsiao JK, Hung Y. Mesoporous silica nanoparticles improve magnetic labeling efficiency in human stem cells. Small. 2008;4(5):619-26. doi: 10.1002/SMLL.200700493, PMID 18491363.

Liu X, Ren Q, Fu F, Zou R, Wang Q, Xin G. CuS@mSiO2-PEG core shell nanoparticles as a NIR light responsive drug delivery nanoplatform for efficient chemo photothermal therapy. Dalton Trans. 2015;44(22):10343-51. doi: 10.1039/C5DT00198F, PMID 25970690.

Ma M, Chen H, Chen Y, Wang X, Chen F, Cui X. Au capped magnetic core mesoporous silica shell nanoparticles for combined photothermo chemo therapy and multimodal imaging. Biomaterials. 2012;33(3):989-98. doi: 10.1016/j.biomaterials.2011.10.017, PMID 22027594.

Lu J, Liong M, Zink JI, Tamanoi F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small. 2007;3(8):1341-6. doi: 10.1002/SMLL.200700005, PMID 17566138.

Zivojevic K, Mladenovic M, Djisalov M, Mundzic M, Ruiz Hernandez E, Gadjanski I. Advanced mesoporous silica nanocarriers in cancer theranostics and gene editing applications. J Control Release. 2021;337:193-211. doi: 10.1016/j.jconrel.2021.07.029, PMID 34293320.

Bhavsar DB, Patel V, Sawant KK. Design and characterization of dual responsive mesoporous silica nanoparticles for breast cancer targeted therapy. Eur J Pharm Sci. 2020;152:105428. doi: 10.1016/j.ejps.2020.105428, PMID 32553643.

Karthikeyan L, Sobhana S, Yasothamani V, Gowsalya K, Vivek R. Multifunctional theranostic nanomedicines for cancer treatment: recent progress and challenges. Biomedical Engineering Advances. 2023;5:100082. doi: 10.1016/j.bea.2023.100082.

Bhavsar D, Gajjar J, Sawant K. Formulation and development of smart pH responsive mesoporous silica nanoparticles for breast cancer targeted delivery of anastrozole: in vitro and in vivo characterizations. Micropor Mesopor Mater. 2019;279:107-16. doi: 10.1016/j.micromeso.2018.12.026.

Hanafi Bojd MY, Jaafari MR, Ramezanian N, Xue M, Amin M, Shahtahmassebi N. Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells. Eur J Pharm Biopharm. 2015;89:248-58. doi: 10.1016/j.ejpb.2014.12.009, PMID 25511563.

Xiao X, Liu Y, Guo M, Fei W, Zheng H, Zhang R. pH-triggered sustained release of arsenic trioxide by polyacrylic acid capped mesoporous silica nanoparticles for solid tumor treatment in vitro and in vivo. J Biomater Appl. 2016;31(1):23-35. doi: 10.1177/0885328216637211, PMID 27059495.

Jia L, Shen J, Li Z, Zhang D, Zhang Q, Liu G. In vitro and in vivo evaluation of paclitaxel loaded mesoporous silica nanoparticles with three pore sizes. Int J Pharm. 2013;445(1-2):12-9. doi: 10.1016/j.ijpharm.2013.01.058, PMID 23384728.

Trzeciak K, Chotera ouda A, Bak sypien II, Potrzebowski MJ. Mesoporous silica particles as drug delivery systems the state of the art in loading methods and the recent progress in analytical techniques for monitoring these processes. Pharmaceutics. 2021;13(7):950. doi: 10.3390/pharmaceutics13070950, PMID 34202794.

Lu J, Liong M, Zink JI, Tamanoi F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small. 2007;3(8):1341-6. doi: 10.1002/smll.200700005, PMID 17566138.

He Y, Liang S, Long M, Xu H. Mesoporous silica nanoparticles as potential carriers for enhanced drug solubility of paclitaxel. Mater Sci Eng C Mater Biol Appl. 2017;78:12-7. doi: 10.1016/j.msec.2017.04.049, PMID 28575958.

Babaei M, Abnous K, Taghdisi SM, Taghavi S, Sh Saljooghi ASh, Ramezani M. Targeted rod shaped mesoporous silica nanoparticles for the co-delivery of camptothecin and survivin shRNA in to colon adenocarcinoma in vitro and in vivo. Eur J Pharm Biopharm. 2020;156:84-96. doi: 10.1016/j.ejpb.2020.08.026, PMID 32882423.

Koohi Moftakhari Esfahani M, Alavi SE, Cabot PJ, Islam N, Izake EL. Application of mesoporous silica nanoparticles in cancer therapy and delivery of repurposed anthelmintics for cancer therapy. Pharmaceutics. 2022;14(8):1579. doi: 10.3390/pharmaceutics14081579, PMID 36015204.

Bhavsar D, Gajjar J, Sawant K. Formulation and development of smart pH responsive mesoporous silica nanoparticles for breast cancer targeted delivery of anastrozole: in vitro and in vivo characterizations. Micropor Mesopor Mater. 2019;279:107-16. doi: 10.1016/j.micromeso.2018.12.026.

Bhavsar DB, Patel V, Sawant KK. Design and characterization of dual responsive mesoporous silica nanoparticles for breast cancer targeted therapy. Eur J Pharm Sci. 2020;152:105428. doi: 10.1016/j.ejps.2020.105428, PMID 32553643.

Han R, Tang K, Hou Y, Yu J, Wang C, Wang Y. Ultralow intensity near infrared light synchronously activated collaborative chemo/photothermal/photodynamic therapy. Biomater Sci. 2020;8(2):607-18. doi: 10.1039/c9bm01607d, PMID 31793930.

Hillegass JM, Blumen SR, Cheng K, MacPherson MB, Alexeeva V, Lathrop SA. Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy. Int J Cancer. 2011;129(1):233-44. doi: 10.1002/IJC.25666, PMID 20830711.

Li L, Tang F, Liu H, Liu T, Hao N, Chen D. In vivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. ACS Nano. 2010;4(11):6874-82. doi: 10.1021/NN100918A, PMID 20973487.

Gary Bobo M, Mir Y, Rouxel C, Brevet D, Basile I, Maynadier M. Mannose-functionalized mesoporous silica nanoparticles for efficient two photon photodynamic therapy of solid tumors. Angew Chem Int Ed Engl. 2011;50(48):11425-9. doi: 10.1002/ANIE.201104765, PMID 21976357.

Griffith KA, Zhu S, Johantgen M, Kessler MD, Renn C, Beutler AS. Oxaliplatin-induced peripheral neuropathy and identification of unique severity groups in colorectal cancer. J Pain Symptom Manage. 2017;54(5):701-706.e1. doi: 10.1016/j.jpainsymman.2017.07.033, PMID 28743660.

Li AW, Sobral MC, Badrinath S, Choi Y, Graveline A, Stafford AG. A facile approach to enhance antigen response for personalized cancer vaccination. Nat Mater. 2018;17(6):528-34. doi: 10.1038/S41563-018-0028-2, PMID 29507416.

Yan K, Zhang Y, Mu C, Xu Q, Jing X, Wang D. Versatile nanoplatforms with enhanced photodynamic therapy: designs and applications. Theranostics. 2020;10(16):7287-318. doi: 10.7150/THNO.46288, PMID 32641993.

Kong M, Tang J, Qiao Q, Wu T, Qi Y, Tan S. Biodegradable hollow mesoporous silica nanoparticles for regulating tumor microenvironment and enhancing antitumor efficiency. Theranostics. 2017;7(13):3276-92. doi: 10.7150/THNO.19987, PMID 28900509.

Song M, Liu C, Chen S, Zhang W. Nanocarrier based drug delivery for melanoma therapeutics. Int J Mol Sci. 2021;22(4):1-19. doi: 10.3390/IJMS22041873, PMID 33668591.

Ding B, Shao S, Yu C, Teng B, Wang M, Cheng Z. Large pore mesoporous silica-coated upconversion nanoparticles as multifunctional immunoadjuvants with ultrahigh photosensitizer and antigen loading efficiency for improved cancer photodynamic immunotherapy. Adv Mater. 2018;30(52):e1802479. doi: 10.1002/ADMA.201802479, PMID 30387197.

Choi JY, Ramasamy T, Kim SY, Kim J, Ku SK, Youn YS. Pegylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi targeted cancer therapy. Acta Biomater. 2016;39:94-105. doi: 10.1016/j.actbio.2016.05.012, PMID 27163403.

Bansal KK, Mishra DK, Rosling A, Rosenholm JM. Therapeutic potential of polymer coated mesoporous silica nanoparticles. Appl Sci. 2020;10(1):289. doi: 10.3390/APP10010289.

Hong SH, Choi Y. Mesoporous silica based nanoplatforms for the delivery of photodynamic therapy agents. J Pharm Investig. 2018;48(1):3-17. doi: 10.1007/S40005-017-0356-2, PMID 30546918.

Shao D, Li M, Wang Z, Zheng X, Lao YH, Chang Z. Bioinspired diselenide-bridged mesoporous silica nanoparticles for dual responsive protein delivery. Adv Mater. 2018;30:e1801198. doi: 10.1002/ADMA.201801198, PMID 29808576.

Duo Y, Yang M, Du Z, Feng C, Xing C, Wu Y. CX-5461-loaded nucleolus targeting nanoplatform for cancer therapy through induction of pro death autophagy. Acta Biomater. 2018;79:317-30. doi: 10.1016/j.actbio.2018.08.035, PMID 30172068.

Sun L, Wang D, Chen Y, Wang L, Huang P, Li Y. Core shell hierarchical mesostructured silica nanoparticles for gene/chemo synergetic stepwise therapy of multidrug resistant cancer. Biomaterials. 2017;133:219-28. doi: 10.1016/j.biomaterials.2017.04.028, PMID 28441616.

Omar H, Jakimoska S, Guillot J, Alsharaeh E, Charnay C, Cunin F. Dendritic mesoporous organosilica nanoparticles with photosensitizers for cell imaging siRNA delivery and protein loading molecules. 2023;28(14):5335. doi: 10.3390/molecules28145335.

Fernandez Lodeiro A, Djafari J, Fernandez Lodeiro J, Duarte MP, Muchagato Mauricio EM, Capelo Martinez JL. Synthesis of mesoporous silica coated gold nanorods loaded with methylene blue and its potentials in antibacterial applications. Nanomaterials (Basel). 2021;11(5):1338. doi: 10.3390/nano11051338, PMID 34069626.

Wang X, Li X, Ito A, Yoshiyuki K, Sogo Y, Watanabe Y. Hollow structure improved anticancer immunity of mesoporous silica nanospheres in vivo. Small. 2016;12(26):3510-5. doi: 10.1002/smll.201600677, PMID 27191183.

Escriche Navarro B, Escudero A, Lucena Sanchez E, Sancenon F, Garcia Fernandez A, Martinez Manez R. Mesoporous silica materials as an emerging tool for cancer immunotherapy. Advanced Science. 2022;9(26):e202200756. doi: 10.1002/advs.202200756.

Yang Y, Lu Y, Abbaraju PL, Zhang J, Zhang M, Xiang G. Multi shelled dendritic mesoporous organosilica hollow spheres: roles of composition and architecture in cancer immunotherapy. Angew Chem Int Ed Engl. 2017;56(29):8446-50. doi: 10.1002/ANIE.201701550, PMID 28467690.

Lee JY, Kim MK, Nguyen TL, Kim J. Hollow mesoporous silica nanoparticles with extra large mesopores for enhanced cancer vaccine. ACS Appl Mater Interfaces. 2020;12(31):34658-66. doi: 10.1021/acsami.0C09484, PMID 32662625.

Dengler EC, Liu J, Kerwin A, Torres S, Olcott CM, Bowman BN. Mesoporous silica supported lipid bilayers (protocells) for DNA cargo delivery to the spinal cord. J Control Release. 2013;168(2):209-24. doi: 10.1016/j.jconrel.2013.03.009. PMID 23517784.

Lerida Viso A, Estepa Fernandez A, Garcia Fernandez A, Marti Centelles V, Martinez Manez R. Biosafety of mesoporous silica nanoparticles towards clinical translation. Adv Drug Deliv Rev. 2023;201:115049. doi: 10.1016/j.addr.2023.115049, PMID 37573951.

Greish K, Thiagarajan G, Ghandehari H. In vivo methods of nanotoxicology; 2012. p. 235-53. doi: 10.1007/978-1-62703-002-1_17.

Mohammadpour R, Dobrovolskaia MA, Cheney DL, Greish KF, Ghandehari H. Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications. Adv Drug Deliv Rev. 2019;144:112-32. doi: 10.1016/j.addr.2019.07.006, PMID 31295521.

Nehoff H, Parayath NN, S Taurin, K Greish. In vivo evaluation of acute and chronic nanotoxicity. Chapter 3. Handbook of Nanotoxicology Nanomedicine and Stem Cell use in Toxicology; 2014. p. 65-86. doi: 10.1002/9781118856017.

De La Harpe KM, Kondiah PP, Choonara YE, Marimuthu T, Du Toit LC, Pillay V. The hemocompatibility of nanoparticles: a review of cell nanoparticle interactions and hemostasis. Cells. 2019;8(10):1209. doi: 10.3390/CELLS8101209, PMID 31591302.

Croissant JG, Fatieiev Y, Almalik A, Khashab NM. Mesoporous silica and organosilica nanoparticles: physical chemistry biosafety delivery strategies and biomedical applications. Adv Healthc Mater. 2018;7(4):831. doi: 10.1002/adhm.201700831, PMID 29193848.

Hosseinpour S, Walsh LJ, Xu C. Biomedical application of mesoporous silica nanoparticles as delivery systems: a biological safety perspective. J Mater Chem B. 2020;8(43):9863-76. doi: 10.1039/d0tb01868f, PMID 33047764.

Izquierdo Barba I, Colilla M, Manzano M, Vallet Regi M. In vitro stability of SBA-15 under physiological conditions. Micropor Mesopor Mater. 2010;132(3):442-52. doi: 10.1016/j.micromeso.2010.03.025.

Braun K, Pochert A, Beck M, Fiedler R, Gruber J, Linden M. Dissolution kinetics of mesoporous silica nanoparticles in different simulated body fluids. J Solgel. Sci Technol. 2016;79:319-27. doi: 10.1007/s10971-016-4053-9/metrics.

Ehlerding EB, Chen F, Cai W. Biodegradable and renal clearable inorganic nanoparticles. Adv Sci (Weinh). 2016;3(2):1500223. doi: 10.1002/advs.201500223, PMID 27429897.

Yu M, Zheng J. Clearance pathways and tumor targeting of imaging nanoparticles. ACS Nano. 2015;9(7):6655-74. doi: 10.1021/acsnano.5b01320, PMID 26149184.